Top Markets
Coin of the day
Aroa Biosurgery Limited Aroa Biosurgery Limited

Aroa Biosurgery Limited

ARX
Rank in Stocks #20200
Aroa Biosurgery Limited operates as a regenerative medicine company dedicated... Aroa Biosurgery Limited operates as a regenerative medicine company dedicated to the development, production, and global distribution of medical solutions for wound and tissue repair. The firm innovatively utilizes extracellular matrix (ECM) technology, with its market presence spanning the United States and international territories. Its product line encompasses Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold, tailored for managing both acute and chronic wounds. Additionally, the company offers Myriad Matrix, an engineered ECM device designed for soft tissue repair, reinforcement, and complex wound treatment, along with Myriad Morcells, a powdered version of Myriad Matrix serving similar soft tissue and complex wound applications. Rounding out its offerings are Reinforced Bioscaffolds, a specialized surgical product employed in ventral hernia repair and abdominal wall reconstruction. Founded in 2007, Aroa Biosurgery Limited is headquartered in Auckland, New Zealand.
Share Price
$0.39848591
Market Cap
$137.67M
Change (1 day)
-1.74%
Change (1 year)
-3.96%
Country
NZ
Trade Aroa Biosurgery Limited (ARX)

Category

Revenue for Aroa Biosurgery Limited (ARX)
Revenue in Aug 2026 TTM: 0
According to Aroa Biosurgery Limited latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Aroa Biosurgery Limited from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
$46.59B -
US
$25.84B -
US
$35.48B -
IE
$21.00B -
US
- -
DE